Cara Therapeutics, Inc. (CARA)
Market Cap | 90.85M |
Revenue (ttm) | 27.17M |
Net Income (ttm) | -111.66M |
Shares Out | 54.08M |
EPS (ttm) | -2.06 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 419,306 |
Open | 1.69 |
Previous Close | 1.69 |
Day's Range | 1.67 - 1.74 |
52-Week Range | 1.59 - 12.81 |
Beta | 0.87 |
Analysts | Strong Buy |
Price Target | 17.50 (+941.67%) |
Earnings Date | Nov 6, 2023 |
About CARA
Cara Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate, including Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic ... [Read more]
Financial Performance
In 2022, CARA's revenue was $41.87 million, an increase of 81.81% compared to the previous year's $23.03 million. Losses were -$85.47 million, -3.35% less than in 2021.
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for CARA stock is "Strong Buy." The 12-month stock price forecast is $17.5, which is an increase of 941.67% from the latest price.
News

Cara Therapeutics Announces Approval of KORSUVA® IV Injection Syringe in Japan for the Treatment of Pruritus in Hemodialysis Patients
STAMFORD, Conn., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patien...

Cara Therapeutics Reports Second Quarter 2023 Financial Results
– 2Q23 total revenue of $6.9M including collaborative revenue of $5.4M from the Company's share of profit of KORSUVA ® (difelikefalin) injection –

Cara Therapeutics Appoints Helen M. Boudreau to Board of Directors
STAMFORD, Conn., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patient...

Cara Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference
STAMFORD, Conn., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patient...

Cara Therapeutics to Announce Second Quarter 2023 Financial Results on August 7, 2023
STAMFORD, Conn., July 24, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patient...

Cara Therapeutics to Present at the Jefferies Healthcare Conference
STAMFORD, Conn., June 01, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patient...

Kapruvia® (difelikefalin) recommended by England's NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus
Recommendation will enable eligible patients in England, Wales and Northern Ireland to access the first licensed treatment for moderate-to-severe chronic kidney disease (CKD)-associated pruritus in ad...

Cara Therapeutics Reports First Quarter 2023 Financial Results
– 1Q23 total revenue of $6.2M including collaborative revenue of $2.8M from the Company's share of profit of KORSUVA ® (difelikefalin) injection –

Cara Therapeutics, Inc. (CARA) to Announce First Quarter 2023 Financial Results on May 15, 2023
Cara Therapeutics to Announce First Quarter 2023 Financial Results on May 15,

Cara Therapeutics to Announce First Quarter 2023 Financial Results on May 15, 2023
STAMFORD, Conn., May 01, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients...

Cara Therapeutics Announces Presentation at the 22nd Annual Needham Virtual Healthcare Conference
STAMFORD, Conn., April 10, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patien...

Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month - Cara Therapeutics (NASDAQ:CARA), AdaptHealth (NASDAQ:AHCO)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Cara Therapeutics Releases Inaugural Environmental, Social, and Governance Report
STAMFORD, Conn., March 14, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patien...
Cara Therapeutics stock sinks on larger-than-expected Q4 earnings miss
Yahoo Finance Live anchors Julie Hyman and Jared Blikre discuss fourth-quarter earnings for Cara Therapeutics.

Cara Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results
– 4Q22 total revenue was $3.3 million including collaborative revenue of $1.1 million from the Company's share of profit of KORSUVA ® (difelikefalin) injection; FY22 revenue was $41.9 million includin...

Cara Therapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023
STAMFORD, Conn., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patient...

Cara Therapeutics Announces Results from the KOMFORT Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Notalgia Paresthetica Published in the New England Journal of Medicine
Publication underscores the importance of data in underrecognized neuropathic itch disorder which lacks an approved treatment Publication underscores the importance of data in underrecognized neuropat...

Cara Therapeutics to Host Capital Markets Day on Thursday, February 16, 2023
STAMFORD, Conn., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patient...

Cara Therapeutics Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference
STAMFORD, Conn., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patient...

Cara Therapeutics Reports Third Quarter 2022 Financial Results
– Net revenue was $16.2M for 3Q22 including profit-sharing revenue of $7.4M from KORSUVA ® (difelikefalin) injection –

Cara Therapeutics to Present at Upcoming Investor Conferences
STAMFORD, Conn., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patient...

Cara Therapeutics to Announce Third Quarter 2022 Financial Results on November 7, 2022
STAMFORD, Conn., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patient...

SWK Holdings' Subsidiary, Enteris BioPharma, Receives $5 Million Milestone Payment from Cara Therapeutics
Milestone payment highlights ongoing clinical progress of Oral KORSUVA™ DALLAS , Oct. 10 2022 /PRNewswire/ -- SWK Holdings Corporation (Nasdaq: SWKH), a life sciences focused specialty finance compan...

Cara Therapeutics Announces Difelikefalin (KORSUVA®) Injection New Drug Application Has Been Submitted in Japan
STAMFORD, Conn., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patien...

Cara Therapeutics Appoints Ryan Maynard as Chief Financial Officer
STAMFORD, Conn., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patien...